Tapeworm, Vertigo and Pancreatitis Drugs Are Being Trialled As COVID-19 Treatments
Included in this news roundup is UF startup Algernon Pharmaceuticals's trials with ifenprodil, a drug used to treat vertigo and bird flu. Algernon is testing the drug's efficacy in preventing lung damage and increasing survivability in patients with COVID-19.
Group of Crimefighters Using VR, Help From Former Crooks To Cut Down Shoplifting
UF Innovate | The Hub's Loss Prevention Research Council is fighting crime by working with former thieves to create VR simulations to help major retailers prevent theft.
Research Underway To Treat COVID-19 Long Hauler Syndrome
In this article, UF Innovate | Sid Martin Biotech resident client Neobiosis founder Ian White explains how his company is using regenerative medicine to develop products to treat coronavirus long hauler syndrome. (Note: the University of Florida Innovate Center mentioned in the story should be UF Innovate | Sid Martin Biotech.)
UF Health Researchers Win $75 Million Grant To Help Develop New Antibiotic
In the medical and military fields, antibiotic-resistant bacteria can be formidable foes. Now, University of Florida Health researchers and their collaborators have a $75 million grant to identify a new, unique antibiotic that will protect public health.
New Resident Client at Sid Martin Biotech to Pave Way for Post-COVID Therapy, Regenerative Medicine Research
The inflammation COVID-19 patients suffer during and post-COVID-19 infection (AKA "Post-COVID Syndrome") will be one of many focuses of a new resident client that recently joined the UF Innovate | Sid Martin Biotech, the world-recognized leader in biotechnology incubation. Neobiosis, which produces regenerative tissues, cells, and extracellular vesicles for research and clinical trials to help the body heal itself—without surgery—will operate a laboratory at the biotech center, located in Alachua.
How Will $1 Million in Artificial Intelligence Research Impact Florida Industry?
The University of Florida announced a $1 million investment into artificial intelligence. Twenty faculty teams will study wide-ranging uses on data analysis in a range of fields from agriculture to education.
Algernon Pharmaceuticals Receives Green Light from DSMB to Conduct Phase 3 Study of Ifenprodil for COVID-19
UF startup Algernon Pharmaceuticals Inc., formerly known as Breathtec Biomedical, a clinical-stage pharmaceutical development company, announced that the external Data and Safety Monitoring Board (“DSMB”) has completed its latest review of the Phase 2b part of the Company’s Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19, and has provided approval for the company to continue on with the Phase 3 part of the study.
Pear, etectRx To Explore Use of Sensors To Help Patients Stick With Digital Therapeutics
Pear Therapeutics is teaming up with UF Innovate | The Hub startup etectRx in a "first of its kind" collaboration examining the use of digital pill solutions with prescription digital therapeutics (PDTs), the latter company announced. As part of the agreement, whose financial terms were not disclosed, the companies will work on developing up to two central nervous system product candidates combining PDTs and adherence sensors.
Abbott Blood Test To Evaluate Mild Concussions Wins FDA Clearance
Doctors soon will have a new way to evaluate patients with concussions: a rapid blood test made by Abbott Laboratories that has been cleared by the U.S. Food and Drug Administration. It’s an advancement that could eliminate the need for some patients to get costly CT scans and the radiation exposure that accompanies them.
Manipulating Milestones in Pandemic Times with AGTC’s Sue Washer
The COVID-19 pandemic continues to disrupt biopharma clinical trials, especially those conducted with at-risk patient populations. From patient recruitment to data collection, clinical trials execution became considerably more challenging in 2020. On this episode of The Business Of Biotech, UF startup and UF Innovate | Sid Martin Biotech graduate AGTC CEO Sue Washer gives us a behind-the-scenes look at the creative measures her company took to serve a geographically dispersed clinical patient population and ensure her company met clinical milestones.
